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AbstrAct
In order to investigate the role of microRNAs in the pathogenesis of different 
B-cell lymhoma subtypes, we have applied an array-based assay to a series of 76 
mixed non-Hodgkin B-cell lymphomas, including Burkitt’s lymphoma (BL), diffuse large 
B-cell lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma (MCL) 
and follicular lymphoma. Lymphomas clustered according to histological subtypes, 
driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster). Since 
the two miRNA clusters are known to be MYC-regulated, we investigated whether this 
would be supported in MYC-driven experimental models, and found that this signature 
separated BL cell lines and a MYC-translocated MCL cell lines from normal germinal 
center B-cells and other B-cell populations. Similar results were also reproduced in 
tissue samples comparing BL and reactive lymph node samples. The same series 
was then quantitatively analyzed for MYC expression by immunohistochemistry and 
MYC protein levels were compared with corresponding miRNA signatures. A specific 
metric was developed to summarize the levels of MYC-related microRNAs and the 
corresponding protein levels. We found that MYC-related signatures are directly 
related to MYC protein expression across the whole spectrum of B-cells and B-cell 
lymphoma, suggesting that the MYC-responsive machinery shows predominantly 
quantitative, rather than qualitative, modifications in B-cell lymphoma. Novel MYC-
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related miRNAs were also discovered by this approach. Finally, network analysis found 
that in BL MYC-related differentially expressed miRNAs could control, either positively 
or negatively, a limited number of hub proteins, including BCL2, CDK6, MYB, ZEB1, 
CTNNB1, BAX and XBP1.
IntroductIon
Non-Hodgkin’s B-cell lymphomas (NHBCL) arise 
following clonal expansion and consequent invasion of 
immune organs by B-cells blocked at a certain step of 
the differentiation process. Genetic abnormalities support 
the transformed state of B-cells in parallel with changes 
in gene expression [1]. Gene expression alterations 
were identified in many NHBCL types, although the 
mechanisms of transcription regulation sustaining the 
transformed state are of difficult comprehension [2, 3]. 
MicroRNAs (miRNAs) are a class of short 
noncoding single-stranded RNA implicated in the 
regulation of mRNA synthesis and translation. Each 
miRNA can bind and regulate multiple transcripts and a 
transcript is under potential control by multiple miRNAs 
[4]. MiRNAs are typical pleiotropic agents which together 
with other transcriptional regulators and the epigenetic 
machinery, are critical for setting the levels of proteins 
for proper cellular functions [5]. The net outcome of 
all actions entails a network of regulatory circuitries, 
including proteins and RNAs fine tuning cellular functions 
for the adaptation to different requirements. 
MiRNAs are important for the regulation of 
translation in physiological and pathological states, 
including the sequential differentiation of B-cells and 
lymphomagenesis [6, 7]. Multiple miRNAs, including 
the miRNA miR-17-92 cluster, miR-34a, miR-125b, miR-
150, miR-181a, and miR-212/132, are essential for a 
correct early B-cell development [8]. During late B-cell 
maturation, downregulation of miR-150 is required for 
germinal center (GC) selection and development of the 
adaptive humoral immune response [9]. Other miRNAs as 
miR-155, miR-181b, miR-15a, miR-28, miR-16, miR-15b, 
miR-34a, miR-9, miR-30, let-7a, miR-125b, miR-217 and 
miR-185, modulate the expression of key proteins essential 
for the B-cell maturation [7]. 
The oncogene MYC can bind 10–15% of the genetic 
loci including many miRNAs [10]. MYC is a double 
face transcription factor since on one hand it supports 
cell proliferation and on the other apoptosis. Aberrant 
function of MYC is a feature of about 60% of all human 
cancers; MYC translocations are present in most Burkitt’s 
lymphomas [11–13] and in 5–15% of DLBCL [14]; MYC 
gains or amplification and rarely MYC translocation 
were complexively detected in 36% of MCL [15]. MYC 
mutations were found in 70% of BL and in 16% of DLBCL 
[16, 17]. The combined effect of MYC translocation and 
specific mutations associate with variable clinical outcome 
in DLBCL [17].
MYC is a potent modulator of transcription of 
miRNAs and vice versa [18]. The identification and 
role of MYC-regulated miRNAs was performed in 
MYC-inducible cell lines models of B-cell lymphoma 
[19, 20]. Histone deacetylation is involved in MYC 
mediated transcriptional repression. MYC, HDAC3, and 
PRC2 were demonstrated to form a repressive complex 
tethered to miR-29 and miR-26a promoter elements to 
epigenetically repress transcription of these miRNAs 
in MYC-expressing lymphoma cells [21]. Enforced 
expression of repressed miRNAs diminished the 
tumorigenic potential of lymphoma cells indicating that 
MYC-repressed miRNAs function as tumor suppressor 
genes. Among miRNAs regulated by MYC, the miR-
17-92 cluster has oncogenic effects dependent from its 
ability to stimulate the cell cycle progression. Precise 
doses of MYC are able to stimulate cell proliferation 
instead of apoptosis [22]. MYC stimulates the BCR 
response via the upregulation of miR-17-92 cluster 
and subsequent suppression of inhibitors required 
to limit BCR. This BCR stimulation resulted in a 
lymphomagenic feed-forward regulatory loop [23]. 
The miRNA signature associated to MYC has been 
characterized in cellular models [19], in liver cancer 
[24], in neuroblastoma [25], in lymphomas known 
to overexpress MYC such as Burkitt’s lymphoma 
and diffuse large B-cell lymphomas [26] and by 
computational methods [27]. These studies applied 
different approaches to reveal the MYC-miRNA 
connection and focused on specific aspects. 
MiRNAs take part in regulatory networks affecting 
proteins level and cellular processes. To contribute to 
clarify the implication of miRNAs in malignant B-cell 
transformation, we first compared the miRNA profiles of 
Burkitt’s lymphoma (BL), diffuse large B-cell lymphoma 
(DLBCL), primary mediastinal B-cell lymphoma (PMBL), 
mantle cell lymphoma (MCL) and follicular lymphoma 
(FL). We identified miRNA signatures able to discriminate 
NHBCLs that involved known MYC targets. To assess if 
this miRNA signature was independent from the specific 
microenvironment of NHBCLs, six BL and two MCL cell 
lines were compared with normal B-cells as reference and 
BL tissues were compared with reactive lymph nodes. To 
study known and new MYC signatures connected with 
miRNAs profile of NHBCLs, we investigated MYC 
expression by immunohistochemistry (IHC) and correlated 
the results with miRNAs levels. Finally, we performed 
network analysis to track down the protein-miRNAs 
network modulated by differentially expressed miRNAs 
in NHBCLs.
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results
differences of mirnA signatures in non-
Hodgkin’s b-cell lymphoma types 
We investigated the miRNAs profile in different 
NHBCLs types having origin from follicular naive or 
germinal center (GC) B-cells. We compared 76 NHBCL 
samples comprising 12 Burkitt’s lymphoma (BL), 13 
diffuse large B-cell lymphoma (DLBCL), 8 primary 
mediastinal B-cell lymphoma (PMBL), 17 mantle cell 
lymphoma (MCL) and 26 follicular lymphomas (FL) 
(Figures 1 and 2). According to the miRNA profiles, 
intratype heterogeneity was shown in each NHBCL 
type. Clusterization procedures split samples in two 
large clusters: a cluster included mainly BL, DLBCL and 
PMBL; the other cluster included mainly FL and MCL 
cases. A total of 110 miRNAs subdivided in three clusters 
were differentially expressed among the five NHBCL 
types at FDR 0.5%, fold change >1.5, (Figure 2). One 
miRNA cluster included miRNAs upregulated in MCL and 
FL. A second cluster included miRNAs upregulated in BL, 
DLBCL and PMBL. A third miRNA cluster encompassed 
mainly miRNAs of the miR-17-92 cluster and paralogues. 
These miRNAs were expressed at a higher level in BL 
and in a minor portion of DLBCL, PMBL, MCL and FL 
cases. The polycistron miR-17-92 cluster, miR-29 family, 
miR-150 and miR-497 showed the highest power of 
discrimination of the five NHBCL types (Table 1).
strong up-regulation of miR-17-92 cluster and 
downregulation of miR-221, miR-222, miR-223 
and miR-224 in bl and Mcl cell lines compared 
to normal b-cells
We investigated whether the differences of 
miRNA profiles observed among NHBCL tissues were 
recapitulated in corresponding lymphoma cell lines. 
To capture the pathological signature in cell lines, we 
compared the miRNAs expression profile of six BL and 
two MCL cell lines (of these, one with known MYC 
overexpression) with normal B-cell populations at diverse 
differentiation stages, ranging from bone marrow CD34+ 
cells to mature post GC activated B-cells from tonsils 
(Figure 3). MiRNAs expression in normal B-cells were in 
part published [28].
BL and MCL cell lines clustered together and close 
to GC B-cells and CD34+ cells. Cell lines and CD34+ 
cells showed many differences but similar high levels of 
miR-17-92 cluster, miR-126 and miR-126* compared to 
other categories. Moreover, the cell lines had lower level 
of miR-221, miR-222, miR-222*, miR-223 and miR-224 
compared to other B-cell populations. Mir-150, which 
is strictly regulated during normal B-cell development, 
was expressed at a level that was lower in cell lines in 
comparison to CD34+ cells and GC B-cells. 
BL cell lines showed homogeneous profiles: only 
members of the miR-181 family, miR-9*, miR-130a and 
miR-130b were variably expressed. The miRNA profile 
of the MCL cell lines was more similar to that of BL cell 
lines than to that of naive B-cells. The main differences 
of miRNA expression between MCL cell lines MAVER-1 
(known to overexpress MYC due to translocation) and 
GRANTA-519 regarded miR-181 family and miR-17-92 
cluster. In particular, MAVER-1 but not GRANTA-519 
showed levels of miR-17-92 cluster similar to those of BL 
cell lines. 
MirnA signature in burkitt’s lymphoma tissues
To verify if the miRNAs signature observed in cell 
lines was reproduced in tissues, we compared the miRNAs 
expression of BL tissues and reactive lymph nodes (LNs) 
as normal reference. BLs clustered separately from 
LNs and 56 miRNAs were differentially expressed: 34 
upregulated and 21 downregulated in BL at FDR 2% and 
fold change >1.5 (Figure 4). Top upregulated miRNAs 
included mir-17-92 cluster, miR-499, mir-206, miR-9*. 
Top downregulated miRNAs were miR-222, miR-221, 
miR-150, miR-29 family, let-7 family, miR-342, miR-155, 
miR-146a, miR-146b and miR-23a. 
MiRNAs deregulated in both cell lines and BL 
tissues were members of miR-17-92 cluster, miR-222, 
miR-221, miR-150, let-7 family members. 
Validation of mirnA expression in nHbcls and 
lns by quantitative rt-Pcr
Expression of 9 miRNAs was validated by 
quantitative RT-PCR in BL, DLBCL, PMBL, MCL, FL 
and LN (Supplementary Figure 1). The 9 miRNAs showed 
significant differences in at least one NHBCL type with 
respect to LN (P < 0.05): let-7a in DLBCL, PMBL and 
BL; miR-9* in FL, MCL, DLBCL, PMBL and BL; miR-
10a in DLBCL and PMBL BL; miR-20b in MCL and BL; 
miR-21 in FL, MCL, DLBCL, PMBL and BL; miR-29a in 
FL, MCL and BL; miR-150 in DLBCL, PMBL and BL: 
miR-155 in FL, MCL, DLBCL, PMBL and BL; miR-222 
in FL, DLBCL, PMBL and BL. 
A MYC signature is deeply embedded into the 
mirnA profile of bl and in a fraction of other 
nHbcl types
The oncogene MYC plays a relevant pathological 
role in NHBCL pathogenesis [29]. In particular, BL is 
known as MYC-driven lymphoma. In addition, MYC 
was demonstrated to be ruling for miRNA expression in 
cellular models and lymphomas [18]. To verify if a MYC-
related miRNA signature showed a phenotypic equivalent 
in the five types of NHBCLs under investigation, we 
assessed MYC expression by IHC in NHBCLs and in LN 
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samples and correlated the MYC+ cell counts with the 
average level of miRNAs demonstrated to be under MYC 
regulation [18] (Figures 2, 5–8). 
Examples of MYC stain in BL, DLBCL, PMBL, 
MCL and FL cases and of LN were reported in Figure 
5. MYC+ cells rate was higher, as expected, in BL cases 
(median 92.5% of cells) with respect to the other NHBCL 
types, namely DLBCL (38.1%), PMBL (37.7%), MCL 
(3.8%), FL (7.9%) and LNs (9.9%). The largest variation 
of MYC+ cells was observed in DLBCL with positive cells 
ranging from 2% to 82%. (Figure 6). 
In five of 12 (41.6%) MCL cases the fraction of 
MYC+ cells was >20%. To confirm the trend of MYC 
expression observed in MCL, we investigated MYC 
expression in 27 additional MCL cases. Here, the median 
of MYC+ fraction was 7.9% and 7 of 27 (26%) cases had 
>20% of MYC+ cells and one showed a MYC staining 
over 70% (Figure 6).
The transcription factor MYC is known to induce 
the downregulation of members of let-7 family, miR-30 
family, miR-29 family, miR-26a and miR-26b, miR-34a, 
miR-146a, miR-150 and miR-195, and the upregulation 
of miRNAs of the miR-17-92 cluster in different models 
[19, 20]. We wondered whether MYC+ cell counts were 
correlated with the expression level of known MYC-
related miRNAs in NHBCLs and LNs. Higher MYC+ 
cell counts correlated with a higher value of what we 
defined the “M parameter” (MYC-upregulated miRNAs 
minus MYC-downregulated miRNAs) (Figure 7). This 
relationship was evident in all NHBCL types and among 
cases of the same lymphoma type. This result suggests that 
a large part of the heterogeneity both intra- and inter-type 
of miRNAs profile observed in the NHBCLs (Figure 2) 
can be attributed to MYC or to be its indirect consequence. 
As a confirmation of the reliability of parameter M, its 
distribution in the five types of NHBCLs was similar to 
that observed for MYC positivity: highest in BL, followed 
by DLBCL, PMBL, MCL, FL and LN, in descending 
order (Figure 8). 
Identification of new MYc-related mirnA 
expression in nHbcls
To discover new MYC-related miRNAs expressions 
in NHBCLs, MYC+ cells counts were correlated with the 
expression level of all miRNA probes. Distribution of P 
values of MYC+ cell counts/miRNA probe relationships 
in the function of Spearman’s correlation values (rho) 
was shown by Volcano plot (Figure 9). P values split in 
two arms according to positive or negative correlation. 
Among positive correlations, miRNAs of the miR-17-92 
cluster showed higher significance together with mir-206, 
miR-219, miR-499, miR-130b, miR-328, miR-324-5p, miR-
330, miR-485, mir-431, miR-192 and other (P < 0.001). 
Among negative correlations, we found miR-29 family, 
miR-150, miR-342, members of let-7 family, miR-26a, 
miR-10a, miR-125a, miR-370, miR-140, miR-26b (P < 
0.001). A complete list of miRNAs significantly correlated 
with MYC+ cell counts in NHBCLs and LNs (P < 0.05) is 
reported in Supplementary Tables 1 and 2. 
MYC is rarely translocated in dlbcl and Mcl 
cases with high MYc+ cells counts
High MYC+ cell counts were detected in BL, as 
expected, and also in a fraction of DLBCL and MCL 
cases (Figure 6). To assess if MYC overexpression cases 
could depend from a gene translocation in DLBCL and 
Figure 1: distribution of 76 samples belonging to bl, dlbcl, PMbl, Mcl and Fl according to their mirnA profile. 
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MCL, we performed fluorescence in situ hybridization 
analysis (FISH). MYC translocation was detected in 1 of 
13 DLBCL (having 81% of MYC+ cells) and in none of 
the 3 MCL cases with high MYC+ cell counts. Instead, 
these 3 MCL cases showed a copy number gain of MYC 
(Supplementary Table 3).
BCL2, CDK6, ZEB1, MYB and BCL6 are hub 
proteins of cellular circuitries under control of 
mirnAs in nHbcls
We performed network analysis of targets of 
miRNAs differentially expressed in BL. To infer 
proteins modulated by miRNAs, we consulted a 
global intracellular protein-protein interactome (http://
dp.univr.it/~laudanna/LCTST/downloads/index.html). 
We identified the nodes involved in the shortest paths 
among experimentally validated miRNA targets. We 
considered the proteins with highest degree (hub) as the 
most perturbed targets in the biological processes under 
investigation. We then generated a network including the 
targets of the miRNAs as mentioned in Materials and 
Methods, and the differentially expressed miRNAs. Using 
this representation, we highlighted the relationship 
between miRNA-related changes and potential protein 
targets. Hub proteins of the network included BCL2, 
Figure 2: levels of mirnAs differentially expressed among bl, dlbcl, PMbl, Mcl and Fl samples. The heat map 
describes the expression levels of 110 single miRNAs differentially expressed among five lymphoma types at FDR 0.5%. At the top of the 
heat map, for each sample is indicated the per cent of MYC+ cells detected by immunohistochemistry.
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table 1: MirnA differentially expressed among bl, dlbcl, PMbl, Fl and Mcl
mirnA Q value mirnA Q value
miR-17-5p 4.9E-14 mir-133b 1.8E-05
miR-29c 1.3E-13 miR-125b 1.8E-05
miR-106a 1.4E-13 mir-184 1.9E-05
miR-20b 3.2E-13 miR-338 1.9E-05
miR-106b 5.0E-13 miR-370 2.1E-05
let-7a 1.2E-12 mir-335 3.1E-05
miR-150 1.4E-12 mir-431 3.5E-05
miR-497 1.4E-12 miR-15a 4.2E-05
miR-20a 1.5E-12 miR-126 4.9E-05
miR-29a 1.7E-12 miR-200c 5.2E-05
miR-29b 1.0E-11 let-7g 5.6E-05
miR-93 1.7E-11 miR-192 6.1E-05
miR-342 2.2E-11 mir-331 7.1E-05
miR-27a 2.3E-11 miR-30e-5p 8.5E-05
miR-374 4.0E-11 miR-32 8.5E-05
miR-26a 6.7E-11 miR-218 1.0E-04
mir-339 1.2E-10 miR-498 1.1E-04
miR-26b 2.3E-10 miR-30c 1.1E-04
miR-146b 3.3E-10 miR-24 1.2E-04
mir-206 4.5E-10 miR-135a 1.9E-04
miR-146a 5.0E-10 miR-99b 2.0E-04
miR-194 5.6E-10 miR-224 2.0E-04
miR-221 1.1E-09 mir-34c 2.0E-04
mir-196b 1.2E-09 miR-410 2.2E-04
miR-326 1.5E-09 miR-199a 2.3E-04
miR-18a 1.5E-09 miR-99a 2.4E-04
miR-7 3.0E-09 mir-424 2.6E-04
miR-328 6.1E-09 miR-28 3.3E-04
miR-212 7.0E-09 miR-409-3p 3.4E-04
mir-140 8.2E-09 miR-30b 3.6E-04
miR-361 1.2E-08 miR-196a 4.5E-04
let-7d 2.2E-08 miR-98 5.4E-04
miR-19b 2.4E-08 mir-193a 5.6E-04
miR-30d 3.9E-08 miR-181d 5.6E-04
mir-10b 6.9E-08 mir-204 5.6E-04
let-7f 7.9E-08 miR-485-3p 6.1E-04
miR-128a 9.7E-08 miR-215 6.2E-04
miR-219 1.0E-07 miR-9* 6.3E-04
mir-340 1.3E-07 miR-181c 6.5E-04
miR-346 1.3E-07 miR-143 6.5E-04
miR-499 1.3E-07 miR-126* 6.6E-04
miR-21 1.3E-07 miR-373* 6.7E-04
miR-9 1.3E-07 miR-153 6.8E-04
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CDK6, MYB, CTNNB1, ZEB1, XBP1 and BAX together 
with 31 miRNAs connected with the seven hub proteins 
(Figure 10).
dIscussIon
MiRNAs play essential roles in the B-cell 
development and their deregulation was a hallmark in 
various lymphoma types [7, 26, 30–35]. To increase our 
comprehension regarding the implication of miRNAs 
in NHBCLs, we first compared 76 lymphoma samples 
belonging to five NHBCL types and identified a set of 
miRNAs able to discriminate among BL, DLBCL, PMBL, 
MCL and FL. NHBCLs, separated in two large clusters: 
a cluster included BL, DLBCL and PMBL cases and 
another cluster included FL and MCL cases. Among the 
110 miRNAs able to discriminate the five lymphomas 
types, members of miR-17-92 cluster and miR-29 family 
represented top rank markers. These two miRNA groups 
showed a higher variance with respect to other miRNAs. A 
group of samples, mostly BL, showed the highest level of 
miR-17-92 cluster and the lowest level of miR-29 family. 
In other NHBCL types, the reverse correlation of the two 
groups of miRNAs was less pronounced. This dichotomy 
was observed by other authors who performed a diverse 
type of comparison among NHBCLs [26, 31, 34, 36, 37]. 
The reverse correlation of miRNAs member of miR-17-92 
cluster and miR-29 family was previously reported as a 
typical pattern dependent from MYC in NHBCLs [26]. 
According to this consideration, we could conclude that 
a MYC signature deeply affects the miRNA profiles of 
NHBCLs. 
We then searched for a confirmation of the miRNA 
signature observed in NHBCL tissues by studying BL 
and MCL cell lines. BL is a typical highly proliferating 
and malignant MYC-driven lymphoma, while MCL is a 
CCND1-positive lymphoma with a heterogeneous clinical 
behaviour. A specific difference between MCL cell lines 
MAVER-1 and GRANTA-519 is the presence of a MYC 
translocation in MAVER-1 but not in GRANTA-519 
[38]. BL in known to share a gene expression program 
with normal GC B-cells [39] and accordingly the cell 
lines showed a miRNA profile more similar to that of 
GC B-cells compared to other normal B-cells. The main 
differences regarded the miR-17-92 cluster, which was 
highly expressed in BL cell lines and in the MCL cell line 
MAVER-1 but not in GRANTA-519. Other differences 
between the six BL cell lines and GC B-cells regarded 
miR-202* 1.5E-07 miR-15b 8.3E-04
miR-125a 1.6E-07 mir-96 8.5E-04
miR-10a 2.2E-07 miR-527 9.3E-04
mir-152 4.1E-07 miR-101 9.3E-04
miR-30a-3p 4.1E-07 miR-181a 1.1E-03
let-7c 4.2E-07 miR-301 1.1E-03
miR-142-5p 6.1E-07 miR-181a* 1.3E-03
miR-155 6.7E-07 miR-181b 1.4E-03
mir-320 8.6E-07 miR-494 1.4E-03
miR-483 1.1E-06 mir-132 1.4E-03
mir-422a 1.3E-06 miR-195 1.5E-03
miR-92 2.1E-06 mir-345 1.5E-03
miR-222 2.7E-06 miR-429 1.5E-03
mir-185 3.3E-06 miR-17-3p 1.5E-03
mir-130b 5.3E-06 miR-324-3p 1.9E-03
miR-30a-5p 6.0E-06 miR-214 1.9E-03
miR-100 6.1E-06 miR-16 2.0E-03
miR-25 6.3E-06 miR-136 2.1E-03
miR-330 6.7E-06 miR-500 2.2E-03
miR-324-5p 7.7E-06 mir-496 2.3E-03
miR-129 8.2E-06 miR-191 2.4E-03
miR-425-3p 1.3E-05 miR-147 2.7E-03
miR-23a 1.4E-05 miR-27b 2.7E-03
mir-211 1.6E-05 miR-23b 3.1E-03
miR-210 1.7E-05 miR-122a 3.9E-03
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the upregulation of miR-126, miR-126* and of miR-
99b and the downregulation of miR-150, miR-221/222 
family (paralogues), miR-223 and miR-224. These same 
miRNAs were heterogeneously expressed in the GC B-cell 
samples, suggesting that BL might derive from a specific 
subpopulation of GC B-cells with proliferating potential. 
The two MCL cell lines showed miRNA profiles 
significantly different from those of naive B-cells, which 
are supposedly their cell of origin. So, it is possible that 
miR-150 downregulation (and the cooperative effect 
resulting of the upregulation of its target genes) is an 
intrinsic feature to the pathogenesis of MCL cells and 
might be related to the presence of activation of the B-cell 
receptor pathway in analogy to GC B-cells [40, 41]. 
The strong downregulation of miR-221/222 family, 
miR-223 and miR-224 in all lymphoma cell lines compared 
to all normal B-cells removes a mechanism of buffering 
and unlocks the expression of their gene targets. In 
contrast, these miRNAs were found upregulated in many 
solid tumors in multiple studies. MiR-221/miR-222 control 
cell migration, proliferation and apoptosis in different 
contexts. MiR-221/miR-222 target KIT in cord blood 
Figure 3: MirnAs expression profiles of bl and Mcl cell lines compared to bone marrow cd34+ cells and normal 
b-cells at different stages of differentiation. MiRNAs expression profile of six BL cell lines and two MCL cell lines compared 
with that of CD34+ cells and normal B-cells at different differentiation stages. GC, germinal center; PB B-cells, peripheral blood B-cells.
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progenitors and their appropriate level is essential for a 
correct hematopoietic development [8, 42]. Mir-223 is 
under control of NOTCH and NF-kB signaling [43]. Mir-
223 was found downregulated in various lymphoma types 
and the downregulation associated with worst prognosis 
[43, 44]. MiR-224 was supposed to be oncogenic in 
consequence of its control of the Wnt pathway through 
Frizzled-5 [45]. Low expression of miR-224 predicted 
poor clinical outcome in DLBCL [46]. According to this 
evidence, we can consider miR-221/miR-222, miR-223 and 
miR-224 as critical mediators of the lymphomagenesis. 
By comparing BL tissues with reactive LNs as 
normal references, we confirmed the upregulation of 
the miR-17-92 cluster, miR-196b, miR-219 and the 
downregulation of the miRNAs miR-150, miR-221, 
miR-222, miR-29c, miR-155, miR-23a and miR-140, 
which were found to be differentially expressed also in 
BL cell lines compared to GC B-cells. Once again, the 
miRNAs with higher discriminating power for BL were 
miRNAs members of the miR-17-92 cluster. The recurrent 
involvement of the miR-17-92 cluster as pathological 
signature in lymphoma cell lines and tissues suggests that 
Figure 4: MirnA profile of bl tissues compared to ln. The heat map shows the levels of miRNAs differentially expressed 
between 14 BL and 11 reactive LN samples at FDR 2%. In table, the list of 56 single miRNAs differentially expressed between BLs and 
LNs. In bold, miRNAs differentially expressed between BL cell lines and GC B-cells.
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the key factor in determining the miRNA signatures could 
be linked to MYC action [18, 22, 25, 47, 48]. According to 
this scenario, the crosstalk between MYC and the MYC-
regulated miRNAs has a central role in the maintenance of 
the transformed state.
To test the hypothesis that miRNAs expression 
levels found in NHBCLs are under MYC influence, we 
determined the fraction of MYC+ cells in NHBCL tissues 
by a software-based approach and correlated the cell 
counts with the level of miRNAs known to be upregulated 
and downregulated by MYC. This quantitative IHC 
approach is original in the study of correlation between 
MYC and miRNAs expression. A higher fraction of 
MYC+ cells was detected in BL than in DLBCL, PMBL, 
MCL, FL and LN, from highest to the lowest. Our data 
highlighted an evident correlation among MYC+ cell 
counts and MYC-related miRNAs level in all NHBCLs 
types. A similar approach based on MYC mRNA and 
miRNA levels correlation was previously applied in 
neuroblastoma [25]. In another study, the MYC-related 
miRNAs were extracted from profiles by comparing the 
miRNA differentially expressed between BL and MYC-
independent NHBCLs [26]. No correlation between MYC 
mRNA level and the expression of miRNAs members 
of the miR-17-92 cluster was found in BL, probably as 
a consequence of the presence of saturating MYC (i.e. 
there’s no dynamic range being MYC always very highly 
expressed) [12]. 
In our analysis, the more clearcut evidence of 
correlation between MYC and miRNAs levels arose 
among the DLBCLs. In fact, in this lymphoma type 
MYC+ cell counts ranged from 2% to 82%, allowing 
Figure 5: examples of MYc stain in bl, dlbcl, PMbl, Mcl, Fl and ln cases. MYC+ cells were quantified in 4 μm 
whole-tissue sections using the rabbit monoclonal antibody anti-MYC Y69 diluted 1:300. Positive cell count was performed using the 
cellSense Dimension software. The per cent of MYC+ cells having a nuclear signal above the background signal showed in each slide was 
the ratio between the number of MYC+ nuclei and 10.000 hematoxylin-stained nuclei. The background signal was assessed on slides of 
reactive LNs showing low frequency nuclear stain. The threshold was set just under the level that allowed to consider as negative the 95% 
of cells and at least 1+ the remaining positive cells, according to the evaluation of an expert pathologist. The per cent value reported on the 
picture refers to the average per cent of MYC+ cells of the sample.
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to test the miRNA signature on a wide dynamic range. 
DLBCL showed a clear correlation between MYC-related 
miRNAs expression and MYC+ cell counts. MiRNA 
profile of DLBCL cases with high number of MYC+ cells 
clustered close to BL cases. A similar trend was observed 
also in MCL, FL and reactive LNs. On the whole, 30.7% 
of MCL cases showed more than 20% of MYC+ cells and 
a correlation with the MYC-related miRNA signature 
that parallel that one of DLBCL. We did not find MYC 
translocation in MCL. Instead, we found MYC gain in 
three MCL cases with higher MYC+ cell counts. These 
data are concordant with the reported relevant incidence 
of MYC abnormalities in MCL (36% of cases with gains, 
amplification or rarely translocations) [15]. 
We identified a novel group of miRNAs whose 
expression was correlated with that of MYC. These 
correlations are not yet supported by experimental 
demonstration. Nevertheless, there is evidence supporting 
a functional connection between some new MYC-related 
miRNAs and MYC. MiR-206 was shown to target 
MAP3K13 and as a consequence to determine MYC 
destabilization [49]. A possible link between miR-219 
and MYC was reported. In medulloblastoma, miR-219 
downregulated CD164 and in consequence MYC was 
degraded [50]. MiR-130b was reported to promote MYC 
expression through the YAZ/TAZ pathway [51]. The 
restoration of miR-340 in breast cancer cell lines lacking 
this miRNA inhibited cell growth by the activation of the 
Wnt pathway and the MYC expression [52]. 
In BL, high level of MYC and founder alterations 
induce a field defect characterized by the aberrant 
activation of PI3K signaling pathway and other changes 
mediated by the non-canonical binding of MYC to other 
proteins and genetic loci [29, 53, 54]. A constitutive 
Figure 6: distribution of MYc+ cell counts in bl, dlbcl, PMbl, Mcl, Fl and ln. MYC expression was assessed 
by immunohistochemistry with anti-MYC monoclonal Ab in BL, DLBCL, PMBL, MCL, FL and LN samples and MYC+ cells were 
subsequently counted using the cellSense software. The per cent of MYC+ cells having a nuclear signal above the background signal was 
the ratio between the number of MYC+ nuclei and 10.000 hematoxylin-stained nuclei. An additional series of 27 MCL cases was assessed 
(thick line cross). Box and whiskers: median, 25–75% interquartile, 95% interval confidence. 
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and disregulated early expression of MYC and the 
synergism between MYC and the MYC-related miRNAs 
can overcome the transcriptional program mediated by 
BCL6. In fact, BCL6 prevents MYC expression in the 
B-cells of the dark zone of the GC and adapts the cellular 
functions to the growth conditions of the lymphoma cells 
[22]. According to this description, we can hypothesize 
that MYC overexpression observed in lymphomas has 
a predominantly quantitative rather than qualitative 
effects on the related miRNA circuitry and other cellular 
process. On the other side, in consequence of the wide 
spectrum of possible targets that is typical of most of 
miRNAs, a stronger miRNA signature under MYC control 
might affect signaling pathways and cellular functions 
responsible of the retention of the pathological features 
and support the growth of the transformed cells.
By network analysis we found that BCL2, CDK6, 
MYB, CTNNB1, ZEB1, XBP1 and BAX are hub protein 
of the network under the control of deregulated miRNAs 
in BL. All these proteins are experimentally validated 
potential direct targets of MYC-related miRNAs and play 
important roles in B-cell development. The 7 proteins were 
not altogether significantly modulated following miR-17-
92 cluster overexpression in oncogenic models [22, 48, 
55–58]. We guess that all miRNAs differentially expressed 
in BL are implicated in the fine tuning of their target 
genes in support of cell growth and that the 7 proteins are 
central to this regulatory network. The finding of BCL2 
Figure 7: distribution of MYc+ cell counts in function of the M parameter in bl, dlbcl, PMbl, Mcl, Fl and 
ln samples. MYC expression was assessed by immunohistochemistry with anti-MYC monoclonal Ab in BL, DLBCL, PMBL, MCL, 
FL and LN and MYC+ cells were subsequently counted using the cellSense software. For each sample, MYC-up-regulated miRNAs and 
MYC-down-regulated miRNAs represent the average level of miRNAs known as up-repulated or down-regulated by MYC, respectively. 
M parameter was calculated for each sample as MYC-up-regulated miRNAs minus MYC-downregulated miRNAs.
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in a MYC-related miRNAs targets network associated 
to BL, lymphoma in which BCL2 protein expression is 
absent, should not surprise. The GC reaction requires a 
transient biphasic MYC protein expression in B-cells: 
early, during their early commitment, and later for reentry 
into the GC dark zone [53]. In contrast, BCL2 expression 
is not required. In fact, BCL2 mRNA and protein are 
scarcely present in the GC B-cells and miRNA could be 
implicated in the repression of BCL2 mRNA. The long 
list of miRNAs that were experimentally demonstrated 
to target BCL2 includes many MYC-related miRNAs 
as miR-17-5p, miR-18a, miR-20a, miR-29 family, let-7 
family, miR-34a, miR-34b, miR-125b (see miRTarBase 
at http://mirtarbase.mbc.nctu.edu.tw/). It remains to be 
determined if and which miRNAs contribute to silencing 
of BCL2 in follicular B-cells. 
In conclusion, we identified miRNA signatures 
across the whole spectrum of NHBCLs as well as in 
BL and MCL cell lines. These comparisons lead to the 
recognition of known and new miRNA clusters correlated 
with MYC+ cell counts. By network analysis, we found 
that BCL2, CDK6, MYB, CTNNB1, ZEB1, XBP1 and 
BAX are hub proteins under the control of deregulated 
miRNAs in BL. Accordingly, we can hypothesize that the 
Figure 8: distribution of M parameter in bl, dlbcl, PMbl, Mcl, Fl and ln. For each sample, MYC-uprepulated 
miRNAs and MYC-downregulated miRNAs represent the average level of miRNAs known as uprepulated or downregulated by MYC, 
respectively. M parameter was calculated for each sample as MYC-upregulated miRNAs minus MYC-downregulated miRNAs.
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7 hub proteins might constitute an additional piece of the 
regulatory circuitry operated by MYC.
MAterIAls And MetHods 
samples
Frozen tissues of 76 NHBCLs and 11 reactive LN 
were examined. NHBCL samples comprised 12 Burkitt’s 
lymphoma, 13 diffuse large B-cell lymphoma, 8 primary 
mediastinal B-cell lymphoma, 17 mantle cell lymphoma 
and 26 follicular lymphomas (Supplementary Table 3). 
Four DLBCL cases were classified as GCB DLBCL and 
9 as non-GC DLBCL according to the IHC expression of 
CD10, BCL6 and MUM1, as proposed by Hans et al. 2004 
[59]. Samples were obtained from patients accessing care 
in the Hematology section of the University of Verona 
Hospital compound between 1992 and 2005. An expert 
pathologist reviewed NHBCLs diagnoses. Biopsy and 
blood samples were obtained after informed consent 
approved by Ethical Committee of Verona University 
Hospital (N. 1828, May 12, 2010 “Institution of cell 
and tissue collection for biomedical research in Onco-
Hematology”). Six BL cell lines Ramos, Raji, Daudi, 
Figure 9: distribution of P values in function of spearman’s correlations (rho) for each mirnA probe. Each point of the 
Volcano plot describes the linkage between the levels of a miRNA probe and the MYC+ cell counts in all lymphoma samples. Red points 
and blue points represent negative and positive correlations, respectively, of miRNAs known as MYC-regulated. Grey points represent 
correlations of miRNAs supposedly not MYC-related.
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Laukes, Namalwa and LY91, and two MCL cell lines 
MAVER-1 and GRANTA-519 (here named GRANTA) 
were studied. 
control cells
Two CD34+ cells samples were from the bone 
marrow of two healthy donors. Twenty-six CD19+ 
normal B-cell samples were studied. Four CD19+ B-cell 
samples were from blood of four healthy donors. Twenty-
two CD19+ normal B-cell samples were prepared from 
nonpathological tonsils after surgical removal at the 
National Institute for Cancer Research of Genova. The 
materials used have been collected under Program 1-IC01 
protocol IC/01/LLC/001 13/12/2001, renewed 28/11/2013. 
The protocols, which considered the collection of the 
informed consent of the patient, were approved by the 
local ethics committee of the IRCCS Azienda Ospedaliera 
Integrata San Martino – IST Istituto Nazionale per la 
Ricerca sul Cancro (Genova). 
cell separation 
CD34+ cells samples were isolated by anti-CD34 
antibody-conjugated magnetic beads and magnetic 
sorting. CD19+ cells were isolated from the peripheral 
blood of healthy donors by positive selection with anti-
CD19 antibody-conjugated magnetic beads and magnetic 
sorting. Normal follicular B-cell isolation was performed 
as reported by Dono et al. [60]. Purity of B lymphocytes 
was at least 95%, according to cytofluorimetric analysis. 
nucleic acids
Five mm sections of NHBCL and LN frozen tissues 
were cut at the cryostat. Tumor cellularity of NHBCLs 
was higher than 70%. Total RNA was isolated from frozen 
sections, sorted cells and cell lines using TRIZOL reagent 
(Invitrogen) according to manufacturer’s protocol. RNA 
concentration and integrity was determined respectively 
by spectrophotometer and agarose gel electrophoresis. 
Quantitative rt-Pcr (qrt-Pcr) 
For each sample and for each miRNA, 5 ng of total 
RNA was converted to cDNA by TaqMan MicroRNA 
Reverse Transcription kit (Applied Biosystems) with 
the miRNA specific primer contained in the TaqMan 
MicroRNA assays (Applied Biosystems). MiRNA 
expression was evaluated in 10 µL total volume in the 
Figure 10: subnetwork of proteins and mirnAs around the two hub proteins with higher degree identified by network 
analysis of targets of mirnA differentially expressed between bl and ln. In grey are the hub proteins. Height of the frame 
is directly proportional to the degree. Framed miRNAs refer to miRNAs involved in the network. MiRNAs without frame refer to other 
miRNAs differentially expressed which targets the proteins in the subnetwork.
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presence of 1× TaqMan Universal Master Mix (Applied 
Biosystems). Taqman assays (Applied Biosystems) 
used for miRNA expression analysis were: 4373169 
for let-7a, 4395342 for miR-9*, 4373153 for miR-10a, 
4373261 for miR-20b, 4373090 for miR-21, 4395223 for 
miR-29a, 4373127 for miR-150, 4395459 for miR-155, 
4395387 for miR-222, 4380911 for RNU44 and 4373384 
for U47. QPCR analysis was performed in duplicate on 
7900HT SDS instrument (Applied Biosystems) and the 
average cycle threshold value was used for subsequent 
calculations. Expression differences among samples were 
determined by the comparative method according to User 
Bulletin #2 (Applied Biosystems) using the average level 
of noncoding RNA RNU44 and U47 as reference.
IHc
MYC+ cells were quantified in 4 μm tissue 
sections using the rabbit monoclonal antibody anti-MYC 
Y69 diluted 1:300 (Epitomics, UK). Immunostaining 
was performed using a BondMax autostainer (Leica 
Biosystems). High resolution images of sections 
counterstained with haematoxylin were captured by 
Aperio slide scanner (Leica Biosystems). Positive cell 
count was performed using the cellSense Dimension 
software (Olympus). The fraction of MYC+ cells having 
a nuclear signal above the background signal in each 
lymphoma and LN sample was the ratio between the 
number of MYC+ nuclei and 10.000 haematoxylin-stained 
nuclei. The background signal was assessed on slides 
of reactive LNs showing a low frequency nuclear stain. 
The threshold was set just under the level that allowed 
considering as negative the 95% of cells and at least 1+ the 
remaining positive cells, according to the evaluation of an 
expert pathologist. 
FIsH
FISH was carried out using dual color IgH-MYC 
and IgH-BCL2 probes (Vysis-Abbott, Olympus, Rome, 
Italy) on serial tissue sections. Briefly, 3 μm sections were 
cut from formalin-fixed paraffin-embedded tissue blocks 
and mounted on positively charged slides. The slides 
were dried for one hour at 60° C then deparaffinized, 
rehydrated, and fixed in methanol/acetic acid 3:1 for 5 min. 
Pretreatment was performed at 85° C for 30 min with 0,1 
citrate buffer (pH 6) solution followed by pepsin (4 mg/
ml in 0.9% NaCl, pH 1.5) treatment for 8 min at 37° C. 
After washing and dehydration, 10 μl probe was applied on 
selected area and sealed with rubber cement. Denaturation 
was performed by incubating the slides at 80° C for 10 
min in a humidified atmosphere (Thermobrite System) 
followed by hybridization overnight at 37° C. The rubber 
cement and the cover slip were removed and the slides 
were washed in 2× SSC/0.3% NP40 for 15 min at room 
temperature and then at 72° C for 2 min. Next, the tissue 
sections were counterstained with DAPI antifade (Prolong 
Gold Antifade Reagent Life Technologies) and examined 
under an ×60 to ×100 oil immersion objective using 
an Olympus BX61 fluorescence microscope equipped 
with filters that visualize the different wavelengths of 
the fluorescent probe. Scoring was performed by one 
experienced pathologist (MB) and one experienced 
biologists (GM). At least 100 neoplastic nonoverlapping 
nuclei were included in the scoring. 
Microarrays 
MicroRNA labeling and hybridization were 
performed using 5 mgmicrograms total RNA, as described 
[52]. We used a multi-species microarray platform 
containing 2284 probes, 1256 for human and 1028 for 
mouse targets, respectively. A total of 353 human mature 
or pre-miR were detectable by the microarray. Each human 
target was matched by at least two probes, with an average 
of 4.3 probes for each target. Hybridization signals were 
detected with Streptavidin-Alexa647 conjugate and 
scanned images (Axon 4000B) were quantified using the 
Genepix 6.0 software (Axon Instruments). To minimize 
the possible batch effect on miRNAs expression, samples 
of the same category were randomized through different 
batches. 
data analysis 
Expression data from microarrays were normalized 
and transformed using the vsn package for R. The 
spots were subsequently classified based on their target 
sequence regardless of the original designation. The 
expression measures for probes matching the same 
miR sequence were summarized using the medpolish 
algorithm, in order to obtain a unique expression figure 
for each target. Clustering analysis was performed using 
the hclust function and the inverse Pearson correlation 
as a distance metric, for both genes and arrays. All the 
clusters were visualized using the Java TreeView software 
(http://jtreeview.sourceforge.net). To select differentially 
expressed genes, we performed either anova or t-tests. To 
take into account multiple hypothesis testing, the FDR 
(false discovery rate) was calculated using the q-value 
package for R. All the calculations were performed using 
the R statistical software (http://www.r-project.org). 
Microarray expression data are available on the 
ArrayExpress at https://www.ebi.ac.uk/arrayexpress/
experiments/E-MTAB-6035.
network analysis 
Experimentally validated target genes (only target 
genes marked as “strong evidence”) of differentially 
expressed miRNAs were retrieved from MirTarBase 4.5 
database [61]. Among the predicted targets, only those 
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included in the GO category “lymphocyte differentiation” 
(GO:0030098) were kept. Using the filtered targets and a 
database of protein interactions (http://dp.univr.it/~laudanna/
LCTST/downloads/index.html) and comprising 14642 
proteins and 270062 edges, we generated a network that 
included the shortest paths joining the primary targets. 
Shortest paths were calculated with PeSca application 3.0 
version implemented in Cytoscape 3.0 [62, 63].
Author contributions
G.M. designed the study, performed molecular 
studies, interpreted data, and wrote the manuscript; S.B. 
designed the study, performed bioinformatic analyses 
and interpreted data; G.T. performed network analyses 
and revised the manuscript; S.Z., collected samples, 
isolated cells and interpreted the results; S.P., M. B. and 
A.B. collected data and interpreted the results; C.G., 
MT.S., PT.K., CM.C. and G.C. revised the manuscript; 
M.K. designed the study and revised the manuscript; 
A.S. designed the study, interpreted data and revised the 
manuscript; A.Z. performed the pathological revision, 
analyzed and interpreted data and wrote the manuscript. 
All authors have read the manuscript and approved the 
submission.
conFlIcts oF Interest
The authors declare no conflict of interest.
FundInG
This work was supported by Associazione Italiana 
Ricerca sul Cancro (AIRC grant n. 12182).
reFerences
1. Rosenquist R, Beà S, Du MQ, Nade l B, Pan-Hammarström 
Q. Genetic landscape and deregulated pathways in B-cell 
lymphoid malignancies. J Intern Med. 2017; 282:371–94.
2. Campo E. Whole genome profiling and other high 
throughput technologies in lymphoid neoplasms—current 
contributions and future hopes. Mod Pathol. 2013; 
26:S97–S110.
3. Staudt LM. Gene expression profiling of lymphoid 
malignancies. Annu Rev Med. 2002; 53:303–318.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of 
human genes are microRNA targets. Cell. 2005; 120:15–20.
5. Ademokun A, Turner M. Regulation of B-cell differentiation 
by microRNAs and RNA-binding proteins. Biochem Soc 
Trans. 2008; 36:1191–1193.
6. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs 
modulate hematopoietic lineage differentiation. Science. 
2004; 303:83–86.
 7. Kotaki R, Koyama-Nasu R, Yamakawa N, Kotani A. 
miRNAs in Normal and Malignant Hematopoiesis. Int J 
Mol Sci. 2017; 18:1495.
 8. Sole C, Larrea E, Di Pinto G, Tellaetxe M, Lawrie CH. 
miRNAs in B-cell lymphoma: Molecular mechanisms and 
biomarker potential. Cancer Lett. 2017; 405:79–89.
 9. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, 
Wang J, Rajewsky N, Bender TP, Rajewsky K. MiR-150 
controls B cell differentiation by targeting the transcription 
factor c-Myb. Cell. 2007; 131:146–159.
10. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, 
Ooi HS, Orlov YL, Shahab A, Yong HC, Fu Y, Weng Z, 
Kuznetsov VA, et al. Global mapping of c-Myc binding 
sites and target gene networks in human B cells. Proc Natl 
Acad Sci U S A. 2006; 103:17834–17839.
11. Pienkowska-Grela B, Rymkiewicz G, Grygalewicz B, 
Woroniecka R, Krawczyk P, Czyz-Domanska K, Walewski J. 
Partial trisomy 11, dup(11) (q23q13), as a defect characterizing 
lymphomas with Burkitt pathomorphology without MYC gene 
rearrangement. Med Oncol. 2011; 28:1589–1595.
12. Robaina MC, Faccion RS, Mazzoccoli L, Rezende LM, 
Queiroga E, Bacchi CE, Thomas-Tikhonenko A, Klumb 
CE. miR-17-92 cluster components analysis in Burkitt 
lymphoma: overexpression of miR-17 is associated with 
poor prognosis. Ann Hematol. 2016; 95:881–891.
13. Salaverria I, Martin-Guerrero I, Wagener R, Kreuz M, 
Kohler CW, Richter J, Pienkowska-Grela B, Adam P, 
Burkhardt B, Claviez A, Damm-Welk C, Drexler HG, 
Hummel M, et al. A recurrent 11q aberration pattern 
characterizes a subset of MYC-negative high-grade B-cell 
lymphomas resembling Burkitt lymphoma. Blood. 2014; 
123:1187–1198.
14. Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos 
NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow 
L, Goodlad J, Buxton J, Neat M, et al. The prognosis of 
MYC translocation positive diffuse large B-cell lymphoma 
depends on the second hit. J Pathol Clin Res. 2015; 
1:125–133.
15. Yi S, Zou D, Li C, Zhong S, Chen W, Li Z, Xiong W, Liu 
W, Liu E, Cui R, Ru K, Zhang P, Xu Y, et al. High incidence 
of MYC and BCL2 abnormalities in mantle cell lymphoma, 
although only MYC abnormality predicts poor survival. 
Oncotarget. 2015; 6:42362–71. https://doi.org/10.18632/
oncotarget.5705.
16. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, 
Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras 
E, Liu X, Powell J, Yang Y, et al. Burkitt lymphoma 
pathogenesis and therapeutic targets from structural and 
functional genomics. Nature. 2012; 490:116–120.
17. Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, 
Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkaer K, Li J, 
Zhang L, Liang H, et al. Clinical and Biologic Significance 
of MYC Genetic Mutations in De Novo Diffuse Large 
B-cell Lymphoma. Clin Cancer Res. 2016; 22:3593–3605.
Oncotarget29770www.oncotarget.com
18. Jackstadt R, Hermeking H. MicroRNAs as regulators and 
mediators of c-MYC function. Biochim Biophys Acta. 
2015; 1849:544–553.
19. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, 
West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT. 
Widespread microRNA repression by Myc contributes to 
tumorigenesis. Nat Genet. 2008; 40:43–50.
20. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, 
Mendell JT. c-Myc-regulated microRNAs modulate E2F1 
expression. Nature. 2005; 435:839–843.
21. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, 
Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, 
Seto E, et al. Coordinated silencing of MYC-mediated miR-
29 by HDAC3 and EZH2 as a therapeutic target of histone 
modification in aggressive B-Cell lymphomas. Cancer Cell. 
2012; 22:506–523.
22. Mihailovich M, Bremang M, Spadotto V, Musiani D, 
Vitale E, Varano G, Zambelli F, Mancuso FM, Cairns DA, 
Pavesi G, Casola S, Bonaldi T. miR-17-92 fine-tunes MYC 
expression and function to ensure optimal B cell lymphoma 
growth. Nat Commun. 2015; 6:8725.
23. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, 
Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies 
B-cell receptor signaling via inhibition of ITIM proteins: 
a novel lymphomagenic feed-forward loop. Blood. 2013; 
122:4220–4229.
24. Cairo S, Wang Y, de Reynies A, Duroure K, Dahan J, 
Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, 
Buendia MA. Stem cell-like micro-RNA signature driven 
by Myc in aggressive liver cancer. Proc Natl Acad Sci U S 
A. 2010; 107:20471–20476.
25. Beckers A, Van Peer G, Carter DR, Mets E, Althoff K, 
Cheung BB, Schulte JH, Mestdagh P, Vandesompele J, 
Marshall GM, De Preter K, Speleman F. MYCN-targeting 
miRNAs are predominantly downregulated during 
MYCNdriven neuroblastoma tumor formation. Oncotarget. 
2015; 6:5204–16. https://doi.org/10.18632/oncotarget.2477. 
26. Robertus JL, Kluiver J, Weggemans C, Harms G, 
Reijmers RM, Swart Y, Kok K, Rosati S, Schuuring E, 
van Imhoff G, Pals ST, Kluin P, van den Berg A. MiRNA 
profiling in B non-Hodgkin lymphoma: a MYC-related 
miRNA profile characterizes Burkitt lymphoma. Br J 
Haematol. 2010; 149:896–899.
27. Xiong L, Jiang W, Zhou R, Mao C, Guo Z. Identification 
and analysis of the regulatory network of Myc and 
microRNAs from high-throughput experimental data. 
Comput Biol Med. 2013; 43:1252–1260.
28. Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, 
Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, 
Adamo A, Krampera M, Scupoli MT, et al. Identification 
of microRNAs implicated in the late differentiation stages 
of normal B cells suggests a central role for miRNA targets 
ZEB1 and TP53. Oncotarget. 2017; 8:11809–26. https://doi.
org/10.18632/oncotarget.14683.
29. Smith SM, Anastasi J, Cohen KS, Godley LA. The impact 
of MYC expression in lymphoma biology: beyond Burkitt 
lymphoma. Blood Cells Mol Dis. 2010; 45:317–323.
30. Caramuta S, Lee L, Ozata DM, Akcakaya P, Georgii-
Hemming P, Xie H, Amini RM, Lawrie CH, Enblad G, 
Larsson C, Berglund M, Lui WO. Role of microRNAs and 
microRNA machinery in the pathogenesis of diffuse large 
B-cell lymphoma. Blood Cancer J. 2013; 3:e152.
31. Di Lisio L, Sanchez-Beato M, Gomez-Lopez G, 
Rodriguez ME, Montes-Moreno S, Mollejo M, Menarguez J, 
Martinez MA, Alves FJ, Pisano DG, Piris MA, Martinez N. 
MicroRNA signatures in B-cell lymphomas. Blood Cancer 
J. 2012; 2:e57.
32. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, 
Deffenbacher K, Lachel CM, Wang C, Rohr J, Guo S, 
Smith LM, Wright G,  et al. Global microRNA expression 
profiling uncovers molecular markers for classification and 
prognosis in aggressive B-cell lymphoma. Blood. 2015; 
125:1137–1145.
33. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, 
Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat 
JS, Hatton CS. Expression of microRNAs in diffuse large 
B cell lymphoma is associated with immunophenotype, 
survival and transformation from follicular lymphoma. 
J Cell Mol Med. 2009; 13:1248–1260.
34. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, 
Wesche KO, Thiere M, Loeffler M, Klapper W, 
Pfreundschuh M, Matolcsy A, Bernd HW, Reiniger L, et al. 
MicroRNA signatures characterize diffuse large B-cell 
lymphomas and follicular lymphomas. Br J Haematol. 
2008; 142:732–744.
35. Sandhu SK, Croce CM, Garzon R. Micro-RNA Expression 
and Function in Lymphomas. Adv Hematol. 2011; 
2011:347137.
36. Hezaveh K, Kloetgen A, Bernhart SH, Mahapatra KD, Lenze 
D, Richter J, Haake A, Bergmann AK, Brors B, Burkhardt 
B, Claviez A, Drexler HG, Eils R,  et al. Alterations of 
microRNA and microRNA-regulated messenger RNA 
expression in germinal center B-cell lymphomas determined 
by integrative sequencing analysis. Haematologica. 2016; 
101:1380–1389.
37. Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, 
Cooper CD, Brown PJ, Troussard X, Mossafa H, Enver 
T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS. 
MicroRNA expression in lymphocyte development and 
malignancy. Leukemia. 2008; 22:1440–1446.
38. Zamo A, Ott G, Katzenberger T, Adam P, Parolini C, Scarpa 
A, Lestani M, Menestrina F, Chilosi M. Establishment of the 
MAVER-1 cell line, a model for leukemic and aggressive 
mantle cell lymphoma. Haematologica. 2006; 91:40–47.
39. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, 
Greiner TC, Weisenburger DD, Rosenwald A, Ott G, 
Muller-Hermelink HK, Gascoyne RD, Delabie J, et al. 
Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 
2006; 354:2431–2442.
Oncotarget29771www.oncotarget.com
40. Bomben R, Ferrero S, D’Agaro T, Dal Bo M, Re A, 
Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, 
Rusconi C, Arcaini L, Rigacci L, et al. A B-cell receptor-
related gene signature predicts survival in mantle cell 
lymphoma: results from the Fondazione Italiana Linfomi 
MCL-0208 trial. Haematologica. 2018; 103:849–56.
41. Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, 
Walchli S, Green MR, Troen G, Liestol K, Beiske K, Houot 
R, Delabie J, Alizadeh AA, et al. Distinct patterns of B-cell 
receptor signaling in non-Hodgkin lymphomas identified by 
single-cell profiling. Blood. 2017; 129:759–770.
42. Gabbianelli M, Testa U, Morsilli O, Pelosi E, Saulle E, 
Petrucci E, Castelli G, Giovinazzi S, Mariani G, Fiori ME, 
Bonanno G, Massa A, Croce CM, et al. Mechanism of 
human Hb switching: a possible role of the kit receptor/miR 
221-222 complex. Haematologica. 2010; 95:1253–1260.
43. Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, 
Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S, 
Amadori A, Ferretti E, Gulino A, et al. Notch and NF-kB 
signaling pathways regulate miR-223/FBXW7 axis in 
T-cell acute lymphoblastic leukemia. Leukemia. 2014; 
28:2324–2335.
44. Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D, Qi J, Zhao Y, Qiu L. 
MicroRNA-223 expression is uniformly down-regulated in B 
cell lymphoproliferative disorders and is associated with poor 
survival in patients with chronic lymphocytic leukemia. Leuk 
Lymphoma. 2012; 53:1155–1161.
45. Liu F, Liu Y, Shen J, Zhang G, Han J. MicroRNA-224 
inhibits proliferation and migration of breast cancer cells 
by down-regulating Fizzled 5 expression. Oncotarget. 2016; 
7:49130–42. https://doi.org/10.18632/oncotarget.9734. 
46. Ni H, Wang X, Liu H, Tian F, Song G. Low expression of 
miRNA-224 predicts poor clinical outcome in diffuse large 
B-cell lymphoma treated with R-CHOP. Biomarkers. 2015; 
20:253–257.
47. He L, Thomson JM, Hemann MT, Hernando-Monge E, 
Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, 
Hannon GJ, Hammond SM. A microRNA polycistron as a 
potential human oncogene. Nature. 2005; 435:828–833.
48. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, 
de Stanchina E, D’Andrea A, Sander C, Ventura A. Genetic 
dissection of the miR-17~92 cluster of microRNAs in Myc-
induced B-cell lymphomas. Genes Dev. 2009; 23:2806–2811.
49. Han H, Chen Y, Cheng L, Prochownik EV, Li Y. 
microRNA-206 impairs c-Myc-driven cancer in a synthetic 
lethal manner by directly inhibiting MAP3K13. Oncotarget. 
2016; 7:16409–19. https://doi.org/10.18632/oncotarget.7653.
50. Shi JA, Lu DL, Huang X, Tan W. miR-219 inhibits the 
proliferation, migration and invasion of medulloblastoma 
cells by targeting CD164. Int J Mol Med. 2014; 34:237–243.
51. Zhu G, Wang Y, Mijiti M, Wang Z, Wu PF, Jiafu D. 
Upregulation of miR-130b enhances stem cell-like phenotype 
in glioblastoma by inactivating the Hippo signaling pathway. 
Biochem Biophys Res Commun. 2015; 465:194–199.
52. Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, 
Ghanbarian H, Mahdian R, Karimipoor M, Soleimani M. 
MicroRNA-340 inhibits the migration, invasion, and 
metastasis of breast cancer cells by targeting Wnt pathway. 
Tumour Biol. 2016; 37:8993–9000.
53. Dominguez-Sola D, Victora GD, Ying CY, Phan RT, Saito M, 
Nussenzweig MC, Dalla-Favera R. The proto-oncogene 
MYC is required for selection in the germinal center and 
cyclic reentry. Nat Immunol. 2012; 13:1083–1091.
54. Korac P, Dotlic S, Matulic M, Zajc Petranovic M, 
Dominis M. Role of MYC in B Cell Lymphomagenesis. 
Genes (Basel). 2017; 8:115.
55. Han YC, Vidigal JA, Mu P, Yao E, Singh I, Gonzalez AJ, 
Concepcion CP, Bonetti C, Ogrodowski P, Carver B, 
Selleri L, Betel D, Leslie C, Ventura A. An allelic series of 
miR-17 approximately 92-mutant mice uncovers functional 
specialization and cooperation among members of a 
microRNA polycistron. Nat Genet. 2015; 47:766–775.
56. Jin HY, Oda H, Lai M, Skalsky RL, Bethel K, Shepherd J, 
Kang SG, Liu WH, Sabouri-Ghomi M, Cullen BR, 
Rajewsky K, Xiao C. MicroRNA-17~92 plays a causative 
role in lymphomagenesis by coordinating multiple 
oncogenic pathways. EMBO J. 2013; 32:2377–2391.
57. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC 
through miR-17-92 suppresses specific target genes 
to maintain survival, autonomous proliferation, and a 
neoplastic state. Cancer Cell. 2014; 26:262–272.
58. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, 
Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone 
JR, Jaenisch R, Sharp PA, Jacks T. Targeted deletion reveals 
essential and overlapping functions of the miR-17 through 92 
family of miRNA clusters. Cell. 2008; 132:875–886.
59. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, 
Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, 
Jaffe ES, Pan Z, Farinha P, Smith LM,  et al. Confirmation of 
the molecular classification of diffuse large B-cell lymphoma 
by immunohistochemistry using a tissue microarray. Blood. 
2004; 103:275–282.
60. Dono M, Zupo S, Leanza N, Melioli G, Fogli M, 
Melagrana A, Chiorazzi N, Ferrarini M. Heterogeneity of 
tonsillar subepithelial B lymphocytes, the splenic marginal 
zone equivalents. J Immunol. 2000; 164:5596–5604.
61. Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, 
Yang CD, Hong HC, Wei TY, Tu SJ, Tsai TR, Ho SY, 
Jian TY, et al. miRTarBase 2016: updates to the 
experimentally validated miRNA-target interactions 
database. Nucleic Acids Res. 2016; 44:D239–247.
62. Scardoni G, Tosadori G, Pratap S, Spoto F, Laudanna C. 
Finding the shortest path with PesCa: a tool for network 
reconstruction. F1000Res. 2015; 4:484.
63. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, 
Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a 
software environment for integrated models of biomolecular 
interaction networks. Genome Res. 2003; 13:2498–2504.
